| Literature DB >> 23721511 |
Kasyapa S Chitta1, A Nazmul H Khan, Noreen Ersing, Abhisek Swaika, Aisha Masood, Aneel Paulus, Abdul Qadeer, Pooja Advani, Taimur Sher, Kena C Miller, Kelvin Lee, Asher A Chanan-Khan.
Abstract
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated neem leaf extract (NLE) after a patient with CLL demonstrated disease regression upon taking oral NLE. NLE-mediated apoptosis was examined in peripheral blood mononuclear cells (PBMCs) from 41 patients with CLL. NLE induced a dose-dependent reduction in CLL cell viability with significant apoptosis observed at 0.06% (w/v) by 24 h. Annexin-V staining and poly(ADP-ribose) polymerase 1 (PARP-1) and caspase 3 cleavage were observed after NLE treatment. However, a pan-caspase inhibitor only partially blocked NLE-mediated cell death. NLE also caused loss of mitochondrial outer membrane permeability and nuclear translocation of apoptosis-inducing factor. Furthermore, NLE treatment resulted in LC3-I cleavage. Biochemical analyses revealed that NLE also inhibits Bcl-2 and p53 proteins. In summary, NLE exhibits anti-leukemic properties in patient primary CLL cells and demonstrates clinical efficacy, warranting further investigation as a potential therapy for CLL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23721511 DOI: 10.3109/10428194.2013.807927
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022